Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LOXO 260

Next Previous
Drug Profile

LOXO 260

Alternative Names: LOX-19260; LOXO-260; LY-3838915

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company; Loxo Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein c-ret inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for phase-I development in Solid-tumours(In adolescents, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in USA (PO)
  • 23 Oct 2024 Pharmacokinetic, adverse events and efficacy data from a phase I trial in Solid tumors presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
  • 12 May 2022 Phase-I clinical trials in Solid tumours (In adolescents, In the elderly, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, In adults) in USA (PO) (NCT05241834)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top